Publikationen, an denen er mitarbeitet MARIA AURORA ASTUDILLO GONZALEZ (10)

2024

  1. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

    eBioMedicine, Vol. 102

2019

  1. New chondrosarcoma cell lines with preserved stem cell properties to study the genomic drift during in vitro/in vivo growth

    Journal of Clinical Medicine, Vol. 8, Núm. 4

  2. The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas

    International Journal of Cancer, Vol. 145, Núm. 1, pp. 254-266

2018

  1. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway

    Neoplasia (United States), Vol. 20, Núm. 1, pp. 44-56

2017

  1. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models

    Neoplasia (United States), Vol. 19, Núm. 6, pp. 460-470

2016

  1. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma

    Oncotarget, Vol. 7, Núm. 21, pp. 30935-30950

2015

  1. Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer

    Free Radical Biology and Medicine, Vol. 85, pp. 45-55

2014

  1. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells

    Stem Cells, Vol. 32, Núm. 5, pp. 1136-1148

2013

  1. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation

    Stem Cells, Vol. 31, Núm. 10, pp. 2061-2072

2009

  1. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells

    International Journal of Cancer, Vol. 125, Núm. 7, pp. 1497-1504